FDA approves belzutifan for VHL kidney cancer
The FDA has approved a new drug called belzutifan for [...]
EIKCS 2021: Future treatments for metastatic kidney cancer
Despite the advances in first-line treatments for metastatic renal cell [...]
FDA grants priority review for HIF-2α inhibitor belzutifan (MK-6482)
The US Food and Drug Administration (FDA) has granted priority [...]
Updated results from a trial with belzutifan for people with advanced kidney cancer
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, [...]
HIF-2α inhibitor belzutifan to be fast-tracked for approval for VHL kidney cancer
Kidney cancers frequently have mutations in a gene called the [...]
ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer
In a small phase 2 study presented at the virtual [...]
2020 top stories in kidney cancer
This article summarises the key breakthroughs in the treatment of [...]
IKCS 2020: Treatment selection in kidney cancer
During this interview, Dr Rana McKay from the University of [...]
HIF2α inhibitor provides significant clinical benefit in patients with VHL kidney cancer
One of the major breakthroughs this year the hypoxia-inducible factor [...]
Future for VHL kidney cancer is bright
Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always [...]
